From BMI to Biology: What the GLP-1 Pill Reveals about Obesity Care

By Shanka Senanayake

With the arrival of new weight-loss drugs comes headlines focused on how convenient

the drugs are and how much weight they can help you lose. The new oral GLP-1 pill is no

exception, allowing for significant weight loss without the weekly injections. However, the real

significance of this medication is not its convenience, it is what it reveals about obesity itself.

Rather than being framed as a matter of personal behavior or body mass index (BMI), obesity is finally being recognized as a chronic metabolic disease that is driven by brain signaling and gut hormones. Growing research and investment in GLP-1 therapies reflect this shift, focusing on the biology of appetite and metabolism rather than the number on the scale.

Beyond the Scale: Understanding Obesity

For decades, doctors have used the BMI scale to diagnose obesity (BMI ≥ 30 kg/m 2 ), but it only tells part of the story, measuring a number and ignoring the biology behind weight and health. BMI became popular because it is easy to use and it draws a broad correlation between excess body weight and health risks, but it does not measure body fat or body fat distribution. This allows individuals with high muscle mass to be identified as obese while some others with excess fat and cardiometabolic risks fly under the radar.

Recent research shows that incorporating additional measures, such as waist-to-hip ratio

and body fat distribution, significantly increases the number of people who are classified as

obese. The new framework also introduces two categories: clinical obesity, where excess fat has already caused organ dysfunction or health problems, and preclinical obesity, where clinical impairment has not yet been caused by the excess fat. Under these new criteria, obesity can be diagnosed in somebody who has a high BMI plus one abnormal anthropometric measure, or somebody with a normal BMI but multiple abnormal anthropometric measures.

GLP-1 and the Gut-Brain Axis

GLP-1 therapies target the biology that underlies obesity, acting directly on the gut-brain

axis rather than simply reducing weight. Glucagon-like peptide-1 (GLP-1) is naturally produced in the gut, and is a hormone that signals the brain to regulate appetite, satiety, and reward. It also influences the metabolism of insulin and glucose. Neural circuits connect the gastrointestinal tract and the central nervous system, backing the effectiveness of GLP-1 receptor agonists as a treatment for obesity. By targeting the brain-gut-microbiome interactions, the drug helps people to feel full sooner, slow their gastric emptying, and improve their metabolic balance.

The new GLP-1 pill is a more convenient form of the already effective weekly injections

like Wegovy or Ozempic, marking a shift in obesity care. Treatments are successfully being

designed to align with the biology of appetite and metabolism, not just to cut down some weight.

Obesity Redefined: Implications for Coverage and Care

As obesity becomes more increasingly recognized as a chronic metabolic disease, its

shifting definition has significant implications for treatment access. In the past, Wegovy and

Ozempic were largely limited to those with a BMI of 30 or higher, excluding many people with

excess body fat and metabolic risks. The new framework with waist-to-hip ratio, body fat

distribution, and clinical/preclinical obesity groups allows more patients to qualify for coverage. This will allow healthcare systems to provide earlier and more targeted interventions, paving away for preventative treatments for clinical obesity for those who need them most.

A New Era in Obesity Care

Emergence of GLP-1 therapies, including the new pill, illustrate a societal shift in how

we understand and treat obesity. Instead of being viewed as a matter of personal behavior,

obesity is being recognized as a chronic metabolic disease caused by complex gut-brain

interactions. By advancing the definition of obesity, we are not only improving diagnoses but

also expanding access to treatments for those who need them but would not have been given them based on BMI. By targeting the biology behind appetite and metabolism, GLP-1 represents a move towards more personalized and informed obesity care.